I never imagined this would happen ~8+ years ago. Just, wow. I'm so grateful to everyone in this community and for all the support and help from the many people that made it possible.

We've got two more positions open for RAs to join AI Proteins! One opening is for our Protein Characterization group led by Alyssa Anderson, and the other is for our Biochemistry group led by Edson Carcamo. These wet lab roles are a perfect for college students who are graduating this spring.

We're recruiting a Research Associate to join our Bioprocess Development team. This is a wet lab role ideally suited for someone graduating college this spring who is excited to join a team pioneering a new therapeutic modality

Check it out! 👇
www.aiproteins.com/open-positio...

AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think ...

I had a great time nerding out about protein design with @nickpolizzi.bsky.social, and an enormous thanks to @biotechtv.bsky.social and @massbio.bsky.social for hosting us!

www.biotechtv.com/post/chris-b...

Industry scores higher than academia for job satisfaction Nature’s salary survey finds that industry researchers are more positive about their careers. Academia must raise its game.

Speaking as someone who had a career in academia before industry - there are many things I love about academia, but my job satisfaction is higher in industry.

I hope things get better for all my friends in academia, because switching isn't the solution for everyone.

www.nature.com/articles/d41...

schedule introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...

We've got Jeff Gray (graylab.jhu.edu) coming to present this month!!

Wednesday, February 25th 2026, starting at 7pm EST in Room 181, Building 68, @MIT

"Antibody language models vs. biology; protein docking denoising diffusion models vs. physics"

bpdmc.org

Chris Bahl on the Conundrum of Biotech Platforms YouTube video by Provolut

Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com!

youtu.be/7O0s5AY46U0

I appreciate all the congratulations for our Series A! I also want to make sure we don't forget an important truth

Funding is not the finish line.

We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference

Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.

The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.

endpoints.news/boston-biote...

Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.

To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.

Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.

The secret language of cells — and how to "speak" it What if medicines could "speak" directly to your cells? Protein designer and TED Fellow Chris Bahl introduces a new generation of miniproteins: AI-designed medicines that can deliver detailed instruct...

My new @ted.com talk from the main stage just went live!

go.ted.com/chrisbahl

🧵👇

schedule introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...

Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale

"Predicting protein folding stability and aggregation propensity using large-scale experiments"

bpdmc.org

We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech

Inteligência Artificial Aplicada às Ciências da Vida YouTube video by Instituto de Estudos Avançados da USP

🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!

www.businesswire.com/news/home/20...

It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology

www.businesswire.com/news/home/20...

As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates

Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases

James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today

What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab

James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!

🧵👇

This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social ‪for the great conversation, and for your passion and excitement for biotech and entrepreneurship!

Zero-shot design of drug-binding proteins via neural selection-expansion Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...

Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social

Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world